Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544642 | 1.00 | ALDH1A1 (0.43) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13544944 | 0.83 | SLC6A2 (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13544941 | 0.83 | SLC6A2 (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15592009 | 0.83 | ALDH1A1 (0.40) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14593819 | 0.83 | SLC6A2 (0.37) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14569618 | 0.83 | ALDH1A1 (0.46) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14311906 | 0.82 | SLC6A2 (0.36) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17972972 | 0.80 | GABRR1 (0.39) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14311983 | 0.80 | ALDH1A1 (0.38) | ALDH1A1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23269565 | 0.79 | GABRR1 (0.44) | ALDH1A1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ALDH1A1 4236/4885SLC6A2 298/4885SLC6A4 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.